Precision BioSciences (NASDAQ:DTIL) added ~6% in the premarket on Wednesday after the gene therapy developer announced initial safety and efficacy data from an early-stage trial for its Hepatitis B ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...

High-precision transportation intelligence, powered by Nearmap high-recency aerial imagery and Ecopia’s AI feature extraction ...

DUBLIN--(BUSINESS WIRE)--The "Precision Medicine Software - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Precision Medicine Software was ...

Nathan Buchbinder is co-founder and chief strategy officer at Proscia, where he guides the company in continuing to set the direction for the future of pathology. He sits at the intersection of the ...

- New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, potentially driven by editing of muscle ...

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts ...

The Defense Innovation Unit last Friday issued a solicitation seeking prototype solutions for airborne magnetic data ...

We have finally arrived in the age of marketing where your company’s strategy around data could be described as the precision and approach that a Formula One (F1) Team takes to racing. F1 cars have ...